You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
|
|---|---|
| Published in |
Frontiers in immunology, August 2015
|
| DOI | 10.3389/fimmu.2015.00418 |
| Pubmed ID | |
| Authors |
Isabelle Le Mercier, J. Louise Lines, Randolph J. Noelle |
| Abstract |
In the last two years, clinical trials with blocking antibodies to the negative checkpoint regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple negative checkpoint regulators protect the host against autoimmune reactions but also restrict the ability of T cells to effectively attack tumors. Releasing these brakes has emerged as an exciting strategy for cancer treatment. Conversely, these pathways can be manipulated to achieve durable tolerance for treatment of autoimmune diseases and transplantation. In the future, treatment may involve combination therapy to target multiple cell types and stages of the adaptive immune responses. In this review, we describe the current knowledge on the recently discovered negative checkpoint regulators, future targets for immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| Switzerland | 1 | 11% |
| Unknown | 5 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 89% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 304 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | <1% |
| Denmark | 2 | <1% |
| Singapore | 1 | <1% |
| Hungary | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Netherlands | 1 | <1% |
| Unknown | 295 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 94 | 31% |
| Student > Ph. D. Student | 38 | 13% |
| Other | 26 | 9% |
| Student > Master | 23 | 8% |
| Student > Bachelor | 23 | 8% |
| Other | 52 | 17% |
| Unknown | 48 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 75 | 25% |
| Immunology and Microbiology | 62 | 20% |
| Medicine and Dentistry | 44 | 14% |
| Biochemistry, Genetics and Molecular Biology | 36 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 5% |
| Other | 17 | 6% |
| Unknown | 56 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2019.
All research outputs
#2,459,250
of 25,371,288 outputs
Outputs from Frontiers in immunology
#2,431
of 31,513 outputs
Outputs of similar age
#31,437
of 277,667 outputs
Outputs of similar age from Frontiers in immunology
#9
of 151 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 31,513 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,667 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 151 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.